2023 年 49 巻 11 号 p. 395-400
To manage the early detection of immune-related adverse events (irAEs), it is recommended to conduct baseline testing before administering immune checkpoint inhibitors (ICIs). Additionally, continued testing is necessary during ICI administration. During ICI treatment, it is important to perform tests such as ACTH, that were not commonly done in traditional cancer chemotherapy. However, ensuring consistent execution of these tests is challenging. Therefore, we developed a dedicated test set specifically for ICIs and implemented a flowchart indicating test values for suspected irAEs and consultation options. In this study, we investigated the overall implementation rate of the designated test items in the test set for patients who received nivolumab or pembrolizumab before and after its implementation. Additionally, we retrospectively examined the rate of consultations with other departments for suspected irAEs. The investigation was conducted during the screening phase and from day 2 to 100. During the screening phase, there was a significant increase in implementation rates from 1 case (1.9％) out of 104 cases to 162 cases (50.9％) out of 318 cases (P < 0.01). Similarly, there was a significant difference during the treatment period. Furthermore, the consultation rate significantly increased from 14 cases (13.5％) out of 104 cases to 74 cases (23.3％) out of 318 cases (P < 0.01). In conclusion, the test set serves as a valuable aid in detecting irAEs, and the flowchart has the potential to contribute to an increased consultation rate.
